eIF3e-IN-1 (Compound 209) is an elF3e inhibitor with an EC50 of 18.3 µM. eIF3e-IN-1 significantly reduces the accumulation of HIF1alpha protein induced by hypoxia and inhibits the acute translation hypoxia response. eIF3e-IN-1 significantly inhibits the expression of ATF4 protein. eIF3e-IN-1 can be used in cancer research, such as in breast cancer studies[1].
